These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 14726972)

  • 1. Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: the old and new evidence.
    Diculescu M; Ciocîrlan M; Ciocîrlan M; Piţigoi D; Becheanu G; Croitoru A; Spanache S
    Rom J Gastroenterol; 2003 Dec; 12(4):283-6. PubMed ID: 14726972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention for colon cancer: new opportunities, fact or fiction?
    Terhaar Sive Droste JS; Tuynman JB; Van Dullemen HM; Mulder CJ
    Scand J Gastroenterol Suppl; 2006; (243):158-64. PubMed ID: 16782636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate.
    Mouzas IA; Papavassiliou E; Koutroubakis I
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):421-5. PubMed ID: 9789142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Colorectal cancer in inflammatory bowel disease].
    Henriksen M; Moum B
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2696-9. PubMed ID: 17952155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
    Chan EP; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
    Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
    Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk factors for ulcerative colitis associated colorectal cancers in a Hungarian cohort of ulcerative colitis patients].
    Lakatos L; Mester G; Erdélyi Z; David G; Pandúr T; Balogh M; Fischer S; Vargha P; Lakatos PL
    Orv Hetil; 2006 Jan; 147(4):175-81. PubMed ID: 16515026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mesalazine in ulcerative colitis. Fewer cases of colorectal carcinoma].
    MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921656
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ
    Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.
    Stange EF
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():64-7. PubMed ID: 16961748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ulcerative colitis. Cancer prevention].
    Schmiegel W; Pox C; Kroesen A
    Z Gastroenterol; 2004 Sep; 42(9):1014-8. PubMed ID: 15455276
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemoprevention: a new way to face colorectal cancer in ulcerative colitis.
    Biasco G; Zannoni U
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):426-7. PubMed ID: 9789143
    [No Abstract]   [Full Text] [Related]  

  • 14. Folate and colorectal cancer: an evidence-based critical review.
    Kim YI
    Mol Nutr Food Res; 2007 Mar; 51(3):267-92. PubMed ID: 17295418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
    Sjöqvist U; Tribukait B; Ost A; Einarsson C; Oxelmark L; Löfberg R
    Anticancer Res; 2004; 24(5B):3121-7. PubMed ID: 15510599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin 2- and beta(2)-microglobulin-deficient mice.
    Carrier J; Medline A; Sohn KJ; Choi M; Martin R; Hwang SW; Kim YI
    Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1262-7. PubMed ID: 14652292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis.
    Rubin DT; LoSavio A; Yadron N; Huo D; Hanauer SB
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1346-50. PubMed ID: 17059900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoprevention of colorectal cancer: feasibility in everyday practice?
    Herszényi L; Farinati F; Miheller P; Tulassay Z
    Eur J Cancer Prev; 2008 Nov; 17(6):502-14. PubMed ID: 18941372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.